When compared to chemotherapy alone, a CCR2 antagonist, CCX827 (NCT02345408), coupled with a chemotherapeutic drugs, FOLFIRINOX, improved patients’ overall survival in advanced pancreatic cancer (211). This evidence concerns the gene CCR2 and pancreatic neoplasm.